Fgfr4 antibodies
AssigneeU3 Pharma GmbH
InventorsJohannes Bange, Jens Niewoehner, Patricia Aus Dem Siepen, Mike Rothe
Life of this patent
Estimating the term…
Abstract
The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.
Claims41
1-40. (canceled)
An antibody that binds to the extracellular domain of FGFR4 and at least partially inhibits FGFR4 activity, wherein the antibody reduces or blocks FGFR4 phosphorylation.
The vector according to claim 69, which is an expression vector and the nucleic acid sequence is operably linked to a control sequence.
A pharmaceutical composition comprising an antibody that binds to the extracellular domain of FGFR4 and at least partially inhibits FGFR4 activity, wherein the antibody reduces or blocks FGFR4 phosphorylation.
Dependencies are inferred from the claim text.